Identificador persistente para citar o vincular este elemento:
https://accedacris.ulpgc.es/jspui/handle/10553/168362
| Campo DC | Valor | idioma |
|---|---|---|
| dc.contributor.author | Naranjo Hernández, Antonio | en_US |
| dc.contributor.author | Falcón, Jaime | en_US |
| dc.contributor.author | Plasencia, María Mercedes | en_US |
| dc.contributor.author | de la Nuez, Fidelina | en_US |
| dc.contributor.author | Moreno, Josefina | en_US |
| dc.contributor.author | Ojeda, Soledad | en_US |
| dc.date.accessioned | 2026-06-08T09:29:16Z | - |
| dc.date.available | 2026-06-08T09:29:16Z | - |
| dc.date.issued | 2025 | en_US |
| dc.identifier.issn | 1889-836X | en_US |
| dc.identifier.other | Scopus | - |
| dc.identifier.uri | https://accedacris.ulpgc.es/jspui/handle/10553/168362 | - |
| dc.description.abstract | Background: chronic use of glucocorticoids (GCs) is the most common cause of secondary osteoporosis (OP). However, the prevention of GC-induced OP remains suboptimal despite its inclusion in OP management guidelines. Objective: to analyze the prophylaxis of GC-induced OP at high doses in clinical practice. Methods: the dispensation of GCs and concomitant treatment for OP was analyzed in a district with 2 health care areas. Patients older than 50 years who were dispensed ≥ 90 tablets of prednisone 30 mg through a pharmacy were included. The following data were collected from health records and the electronic pharmacy application: age, sex, reason for using GCs, number of prednisone containers dispensed, bone densitometry performed, and any concomitant use of bisphosphonates or denosumab. Results: a total of 427 patients were included (mean age 66 years M 51 % women). The most frequent body systems involved were respiratory (46 %), cutaneous (10 %), rheumatic (9 %) and neurologic (8 %). OP prophylaxis was dispensed in 59 cases (13.8 %). In the multivariate analysis, prophylaxis was associated with age > 70 years (OR, 4.23; 95 %CI, 2.11-8.49), female sex (OR, 3.15; 95 %CI, 1.47-6.74), having a rheumatic OR, neurologic disease (OR, 5.33; 95 %CI, 2.53-11.23), a bone densitometry assessment (OR, 3.55; 95 %CI, 1.66-7.57) and dispensation of > 120 prednisone tablets from the pharmacy (OR, 2.31; 95 %CI, 1.14-4.70). Conclusion: in our setting, GC-induced OP prophylaxis was definitely suboptimal. Training sessions are needed for doctors who prescribe high doses of GCs, and electronic prescription alerts should be implemented. | en_US |
| dc.language | spa | en_US |
| dc.relation.ispartof | Revista de Osteoporosis y Metabolismo Mineral | en_US |
| dc.source | Revista de Osteoporosis y Metabolismo Mineral [ISSN 1889-836X],v. 17 (3), p. 128-133, (Enero 2025) | en_US |
| dc.subject | 32 Ciencias médicas | en_US |
| dc.subject | 320108 Ginecología | en_US |
| dc.subject | 321315 Traumatología | en_US |
| dc.subject.other | Glucocorticoides | en_US |
| dc.subject.other | Osteoporosis | en_US |
| dc.subject.other | Prophylaxis | en_US |
| dc.subject.other | Profilaxis | en_US |
| dc.subject.other | Glucocorticoids | en_US |
| dc.title | Profilaxis de la osteoporosis en pacientes tratados con dosis elevadas de glucocorticoide | en_US |
| dc.title.alternative | Osteoporosis prophylaxis in patients on high-doses glucocorticoids | en_US |
| dc.type | info:eu-repo/semantics/Article | en_US |
| dc.type | Article | en_US |
| dc.identifier.doi | 10.20960/RevOsteoporosMetabMiner.00072 | en_US |
| dc.identifier.scopus | 105040366398 | - |
| dc.contributor.orcid | NO DATA | - |
| dc.contributor.orcid | NO DATA | - |
| dc.contributor.orcid | NO DATA | - |
| dc.contributor.orcid | NO DATA | - |
| dc.contributor.orcid | NO DATA | - |
| dc.contributor.orcid | NO DATA | - |
| dc.contributor.authorscopusid | 7003297397 | - |
| dc.contributor.authorscopusid | 60655486400 | - |
| dc.contributor.authorscopusid | 60654206200 | - |
| dc.contributor.authorscopusid | 60654942000 | - |
| dc.contributor.authorscopusid | 60655120800 | - |
| dc.contributor.authorscopusid | 8654250900 | - |
| dc.identifier.eissn | 2173-2345 | - |
| dc.description.lastpage | 133 | en_US |
| dc.identifier.issue | 3 | - |
| dc.description.firstpage | 128 | en_US |
| dc.relation.volume | 17 | en_US |
| dc.investigacion | Ciencias de la Salud | en_US |
| dc.type2 | Artículo | en_US |
| dc.utils.revision | Sí | en_US |
| dc.date.coverdate | Enero 2025 | en_US |
| dc.identifier.ulpgc | Sí | en_US |
| dc.contributor.buulpgc | BU-MED | en_US |
| item.grantfulltext | open | - |
| item.fulltext | Con texto completo | - |
| crisitem.author.dept | Departamento de Ciencias Médicas y Quirúrgicas | - |
| crisitem.author.orcid | 0000-0002-2013-6664 | - |
| crisitem.author.fullName | Naranjo Hernández, Antonio | - |
| Colección: | Artículos | |
Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.